BOOK
Modern Management of High Grade Glioma, Part I, An Issue of Neurosurgery Clinics - E-Book
(2012)
Additional Information
Book Details
Abstract
Standard therapy for high grade glioma is a topic that is evolving, timely, and relevant. Guest Editors Isaac Yang, MD and Seunggu Han, MD have assembled a group of experts to highlight the latest updates on various forms of management of high grade glioma. Some of the articles included in this issue focus on Extent of Resection for Glioblastoma; Role of adjuvant radiation therapy; Survival benefit of the Temozolomide protocol; Alternative chemotherapeutic agents; The role of avastin; Radiology; Pseuodprogression and Treatment effect; Pathology; Medical Management; Management of insular gliomas; Use of motor mapping; GBM treatment with clinical trials for surgical resection; Clinical trials with immunotherapy; Clinical trials for small molecule inhibitors; Future role of CED for GBM treatment; Application of a vault nanoparticle therapy for GBM therapy; Management of high grade gliomas in pediatric populations; Targeting Glioma Stem Like Cells with a focus on CD 133; and Potential Role for STAT3 inhibitors in glioblastoma.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Neurosurgery Clinics of North America | i | ||
| Copyright Page | ii | ||
| Table of Contents | vii | ||
| Contributors | iii | ||
| Preface | xiii | ||
| Chapter 1. Current Surgical Management of Insular Gliomas | 199 | ||
| ANATOMY OF INSULAR GLIOMA AND SURGICAL APPROACHES | 199 | ||
| CLINICAL CHARACTERISTICS AND DIAGNOSIS OF INSULAR GLIOMAS | 200 | ||
| SURGICAL RESULTS AND ONCOLOGICAL OUTCOME | 203 | ||
| NEUROLOGIC DEFICITS AND FUNCTIONAL OUTCOME | 204 | ||
| NONSURGICAL MANAGEMENT ALTERNATIVES | 204 | ||
| SUMMARY | 205 | ||
| REFERENCES | 205 | ||
| Chapter 2. The Rise and Fall of \"Biopsy and Radiate\": A History of Surgical Nihilism in Glioma Treatment | 207 | ||
| COMMONLY HELD VIEWS ABOUT GLIOMA TREATMENT | 207 | ||
| NIHILISM IN GLIOMA SURGERY | 207 | ||
| IS NIHILISM JUSTIFIED? | 208 | ||
| IS AN AGGRESSIVE SURGICAL PHILOSOPHY WARRANTED? | 210 | ||
| IS THE RISK WORTH IT? | 211 | ||
| MARGINS IN GLIOMA SURGERY | 211 | ||
| FUNDAMENTAL PROBLEMS WITH NIHILISM FOR PATIENTS WITH GLIOMA | 212 | ||
| CONCLUSION: THE FUTURE OF GLIOMA SURGERY | 213 | ||
| REFERENCES | 213 | ||
| Chapter 3. The Use of Motor Mapping to Aid Resection of Eloquent Gliomas | 215 | ||
| EARLY WORK ON THE MOTOR CORTEX | 215 | ||
| PRINCIPLES OF DIRECT CORTICAL STIMULATION | 216 | ||
| ECS MAPPING AND IDENTIFICATION OF ROLANDIC CORTEX | 218 | ||
| OBSERVATIONAL MAPPING TECHNIQUES | 219 | ||
| SURGICAL CONSIDERATIONS FOR FUNCTIONAL MOTOR MAPPING | 221 | ||
| SUMMARY | 221 | ||
| REFERENCES | 221 | ||
| Chapter 4. Characteristics and Treatment of Seizures in Patients with High-Grade Glioma: A Review | 227 | ||
| SURGICAL AND ADJUVANT TREATMENT OF HGGS ASSOCIATED WITH EPILEPSY | 229 | ||
| ANTIEPILEPTIC MEDICATIONS IN PATIENTS WITH HGG | 230 | ||
| SUMMARY AND RECOMMENDATIONS | 231 | ||
| REFERENCES | 232 | ||
| Chapter 5. Pathology: Commonly Monitored Glioblastoma Markers: EFGR, EGFRvIII, PTEN, and MGMT | 237 | ||
| EGFR | 237 | ||
| MGMT | 241 | ||
| SUMMARY | 242 | ||
| REFERENCES | 242 | ||
| Chapter 6. The Role of Adjuvant Radiation Therapy in the Management of High-Grade Gliomas | 247 | ||
| RADIOBIOLOGY | 247 | ||
| DEVELOPMENT OF THE CURRENT RADIATION TREATMENT PARADIGM | 249 | ||
| RADIATION SENSITIZERS | 250 | ||
| PREDICTORS OF RESPONSE TO RADIATION THERAPY | 250 | ||
| MODIFICATION OF RADIATION DELIVERY TYPES | 251 | ||
| SUMMARY | 253 | ||
| REFERENCES | 253 | ||
| Chapter 7. Radiation Options for High-Grade Gliomas | 259 | ||
| DEFINITION OF THE EXTENT OF RADIATION | 260 | ||
| ESTABLISHMENT OF RADIATION AS PART OF THE MULTIMODALITY TREATMENT OF HGGS | 260 | ||
| IMPORTANCE OF SURGERY FOR RADIATION TREATMENT | 261 | ||
| MODERN TECHNIQUES OF RADIATION FOR HGGs BASED ON MODERN IMAGING | 261 | ||
| ROLE OF STEREOTACTIC RADIOSURGERY AND STEREOTACTIC RADIOTHERAPY FOR MANAGEMENT OF HGGs | 263 | ||
| SUMMARY | 266 | ||
| REFERENCES | 266 | ||
| Chapter 8. Radiology: Criteria for Determining Response to Treatment and Recurrence of High-Grade Gliomas | 269 | ||
| DEVELOPMENT OF CRITERIA FOR DETERMINING RESPONSE | 269 | ||
| DEVELOPMENT OF THE CURRENT STANDARD CRITERIA (RANO CRITERIA) | 271 | ||
| EMERGING NEUROIMAGING MODALITIES TO ASSESS TUMOR RESPONSE | 272 | ||
| SUMMARY | 275 | ||
| REFERENCES | 275 | ||
| Chapter 9. Pseudoprogression and Treatment Effect | 277 | ||
| PSEUDOPROGRESSION: EARLY TRANSIENT ENHANCING LESIONS | 277 | ||
| RADIATION NECROSIS: DELAYED ENHANCING LESIONS | 278 | ||
| ANTIANGIOGENIC THERAPY FOR GLIOBLASTOMA: RADIOLOGIC AND NONRADIOLOGIC BIOMARKERS OF EFFICACY | 281 | ||
| RESPONSE ASSESSMENT IN NEURO ONCOLOGYCRITERIA FOR HIGH-GRADE GLIOMAS | 282 | ||
| DISTINGUISHING TREATMENT EFFECT OR PSEUDOPROGRESSION FROM TRUE PROGRESSION | 282 | ||
| SUMMARY | 284 | ||
| REFERENCES | 284 | ||
| Chapter 10. The Role of BCNU Polymer Wafers (Gliadel) in the Treatment of Malignant Glioma | 289 | ||
| ANIMAL AND PHARMACOKINETIC STUDIES | 289 | ||
| HUMAN TRIALS WITH SINGLE-AGENT BCNU WAFERS | 290 | ||
| LIMITATIONS OF BCNU WAFERS IN MALIGNANT GLIOMA | 290 | ||
| COMBINATION TRIALS WITH GLIADEL | 293 | ||
| FUTURE DIRECTIONS | 293 | ||
| SUMMARY | 293 | ||
| REFERENCES | 293 | ||
| Chapter 11. Alternative Chemotherapeutic Agents: Nitrosoureas, Cisplatin, Irinotecan | 297 | ||
| CHEMOTHERAPY FOR HIGH-GRADE GLIOMA | 297 | ||
| CISPLATIN | 297 | ||
| IRINOTECAN | 298 | ||
| NITROSOUREAS | 300 | ||
| CCNU | 300 | ||
| BCNU | 302 | ||
| FOTEMUSTINE | 304 | ||
| SUMMARY | 305 | ||
| REFERENCES | 305 | ||
| Chapter 12. Temozolomide and Other Potential Agents for the Treatment of Glioblastoma Multiforme | 307 | ||
| MECHANISM OF ACTION AND PHARMACOKINETICS | 309 | ||
| SIDE EFFECTS AND QUALITY OF LIFE | 310 | ||
| DOSAGE AND SCHEDULING | 311 | ||
| TMZ AND RADIATION THERAPY | 313 | ||
| TMZ AND IMMUNOTHERAPY | 313 | ||
| SUPPLEMENTAL, COMBINATION, AND ALTERNATIVE THERAPIES | 313 | ||
| FDA-APPROVED THERAPIES | 315 | ||
| SUMMARY | 316 | ||
| ACKNOWLEDGMENTS | 316 | ||
| REFERENCES | 316 | ||
| Chapter 13. Superselective Intra-Arterial Cerebral Infusion of Novel Agents After Blood–Brain Disruption for the Treatment of Recurrent Glioblastoma Multiforme: A Technical Case Series | 323 | ||
| ILLUSTRATIVE CASES | 324 | ||
| DISCUSSION | 326 | ||
| SUMMARY | 328 | ||
| REFERENCES | 328 | ||
| Chapter 14. The Role of Avastin in the Management of Recurrent Glioblastoma | 331 | ||
| ANGIOGENESIS | 332 | ||
| AVASTIN IN CLINICAL TRIALS | 334 | ||
| EVALUATION OF CLINICAL EFFICACY | 335 | ||
| OTHER ANTIANGIOGENIC DRUGS | 338 | ||
| OTHER APPLICATIONS OF AVASTIN | 338 | ||
| SUMMARY | 339 | ||
| REFERENCES | 339 | ||
| Chapter 15. Management of Multifocal and Multicentric Gliomas | 343 | ||
| EPIDEMIOLOGY | 343 | ||
| DEFINITION: MULTIFOCAL VERSUS MULTICENTRIC TUMORS | 343 | ||
| PATHOGENESIS | 344 | ||
| PATHOLOGY | 344 | ||
| DIAGNOSIS | 344 | ||
| TREATMENT | 345 | ||
| PROGNOSIS | 348 | ||
| SUMMARY | 348 | ||
| REFERENCES | 348 | ||
| Index | 351 |